CRISPR Therapeutics
CRISPR Therapeutics Raises $337M in Follow-on Offering
Quick Facts
CRISPR Therapeutics Raises $337M in Follow-on Offering
CRISPR Therapeutics has successfully raised $337M in a Follow-on Offering at a $8B valuation led by Versant Ventures, Bayer, Vertex Pharmaceuticals.
Company Overview
CRISPR Therapeutics is a Biotech company headquartered in Aeschenvorstadt 36, Basel 4051, Switzerland, founded in 2013 with 500+ employees.
Gene-based medicines using CRISPR/Cas9
Fundraising Details
- Amount Raised: $337M
- Round Type: Follow-on Offering
- Valuation: $8B
- Date: 2024-09-04
- Investors: Versant Ventures, Bayer, Vertex Pharmaceuticals
About CRISPR Therapeutics
Gene-based medicines using CRISPR/Cas9 The company is positioned in the Biotech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Aeschenvorstadt 36, Basel 4051, Switzerland
- Founded: 2013
- Team Size: 500+
- Industry: Biotech
What This Means
This funding round demonstrates strong investor confidence in CRISPR Therapeutics's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. CRISPR Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $8B valuation marks an important milestone for CRISPR Therapeutics, positioning the company among notable players in the Biotech industry.
Looking Ahead
With this new capital, CRISPR Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2024-09-04. For more information about CRISPR Therapeutics, visit their headquarters at Aeschenvorstadt 36, Basel 4051, Switzerland.
About the Author
Related Company Reports
Anthropic Raises $2B in Series D
Anthropic, a AI/ML company based in San Francisco, CA, has raised $2B in Series D at a $18B valuation led by Menlo Ventures, Spark Capital, Google.
xAI Raises $6B in Series C
xAI, a AI/ML company based in San Francisco, CA, has raised $6B in Series C at a $40B valuation led by Sequoia Capital, a16z, Valor Equity.
Adept AI Raises $350M in Series B
Adept AI, a AI/ML company based in San Francisco, CA, has raised $350M in Series B at a $1B valuation led by General Catalyst, Spark Capital, Addition.